This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PharmaPoint: Rheumatoid Arthritis - India Drug Forecast And Market Analysis Event-Driven Update

9.2 Bibliography 67

9.3 Methodology 73

9.4 Forecasting Methodology 73

9.4.1 Diagnosed Rheumatoid Arthritis Patients 73

9.4.2 Percent Drug-treated Patients 74

9.4.3 Drugs Included in Each Therapeutic Class 74

9.4.4 Launch and Patent Expiry Dates 75

9.4.5 General Pricing Assumptions 75

9.4.6 Individual Drug Assumptions 76

9.4.7 Generic Erosion 80

9.4.8 Pricing of Pipeline agents 80

9.5 Physicians and Specialists Included in this Study 81

9.6 Primary Research - Prescriber Survey 81

9.7 About the Authors 82

9.7.1 Analysts 82

9.7.2 Global Head of Healthcare 83

9.8 About GlobalData 84

9.9 Contact Us 84

9.10 Disclaimer 84

List of Tables

Table 1: Symptoms of Rheumatoid Arthritis 14

Table 2: Treatment Guidelines for Rheumatoid Arthritis 18

Table 3: Top Three Biologics Prescribed for Moderate-Severe Rheumatoid Arthritis by Market 21

Table 4: Treatment Guidelines for Rheumatoid Arthritis 25

Table 5: Product Profile - Enbrel 27

Table 6: 10 year Open-label Safety and Efficacy Trial of Enbrel: Efficacy Results at 11 years for Completers 28

Table 7: 10 year Open-label Safety and Efficacy Trial of Enbrel: Safety Results Overall 29

Table 8: Enbrel SWOT Analysis, 2012 31

Table 9: Product Profile - Remicade 33

Table 10: Remicade SWOT Analysis, 2012 35

Table 11: Product Profile - Orencia 37

Table 12: Orencia SWOT Analysis, 2012 39

Table 13: Product Profile - Actemra/RoActemra 41

Table 14: Actemra/RoActemra SWOT Analysis, 2012 43

Table 15: Product Profile - Rituxan 45

Table 16: Rituxan SWOT Analysis, 2012 47

Table 17: Product Profile - Methotrexate 49

Table 18: Methotrexate SWOT Analysis, 2012 50

Table 19: Summary of Minor Therapeutic Classes, 2012 51

Table 20: Overall Unmet Needs - Current Level of Attainment 52

Table 21: Clinical Unmet Needs - Gap Analysis, 2012 56

Table 22: Rheumatoid Arthritis - Phase Pipeline, 2012 58

Table 23: Sales Forecasts ($m) for Rheumatoid Arthritis in India 61

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,596.35 -350.33 -1.95%
S&P 500 2,057.64 -43.85 -2.09%
NASDAQ 4,958.4680 -122.0370 -2.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs